Literature DB >> 26697466

How to cope with a temporarily aborted transplant program: solutions for a prolonged waiting period.

Frédéric Vanden Eynden1, Martine Antoine1, Bachar El Oumeiri1, Marie-Luce Chirade1, Jean-Luc Vachiéry1, Guido J Van Nooten1.   

Abstract

BACKGROUND: Due to budgetary restrictions our university heart transplant program came to a standstill to be gradually restarted early 2011. Consequently waiting-times for transplantation increased dramatically beyond the usual 10-15 months. We reviewed the clinical results of this peculiar transplant program over the past 4 years.
METHODS: Since March 2011 until February 2015, 65 patients (age 48±23 years) were listed for heart transplantation. Eight patients (11%) of whom three in high emergency were transplanted without any form of mechanical assistance. Fifty-one patients required a left ventricular assist device (LVAD) Heartware (Heartware Inc., Miami Lakes, FL, USA) as a bridge-to-transplant due to terminal heart failure. Merely 5 listed patients remain without assistance.
RESULTS: One patient without assistance and 11 LVAD patients (22%) died on the waiting-list. Meanwhile 10 LVAD patients were transplanted after a 2-year waiting time (770±717 days). Four transplanted patients died of early graft failure none after LVAD explantation. Survival at 1 and 3 years was respectively 78 (72%) and 83 (78%) for transplanted and assisted patients (log-rank P=0.056). Cox multivariable regression analysis identified crash-to-burn patients (P=0.002) and waiting-times over 2 years (P=0.044) as risk factors for early death, while age above 60 (P=0.008) and ischemic aetiology (P=0.029) and pulmonary hypertension (P=0.092) were risk factors for survival.
CONCLUSIONS: In times of donor shortage mechanical assistance proves very effective as bridge-to-transplant in patients for whom candidacy follows the standard inclusion procedures. In our settings, a steep increase in LVAD implantation served to salvage patients for whom transplantation became jeopardized due to an ever increasing waiting-time. Circulatory LVAD support could be considered as primary therapy in the future.

Entities:  

Keywords:  Transplantation; bridge; explant; left ventricular assist device (LVAD); waiting-list

Year:  2015        PMID: 26697466      PMCID: PMC4669321          DOI: 10.3978/j.issn.2305-5839.2015.11.30

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  18 in total

1.  Continuous flow left ventricular assist device outcomes in commercial use compared with the prior clinical trial.

Authors:  Ranjit John; Yoshifumi Naka; Nicholas G Smedira; Randall Starling; Ulrich Jorde; Peter Eckman; David J Farrar; Francis D Pagani
Journal:  Ann Thorac Surg       Date:  2011-10       Impact factor: 4.330

2.  Extracorporeal membrane oxygenation as perioperative right ventricular support in patients with biventricular failure undergoing left ventricular assist device implantation.

Authors:  Mirela Scherer; Abdul Sami Sirat; Anton Moritz; Sven Martens
Journal:  Eur J Cardiothorac Surg       Date:  2010-11-10       Impact factor: 4.191

3.  Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation.

Authors:  Keith D Aaronson; Mark S Slaughter; Leslie W Miller; Edwin C McGee; William G Cotts; Michael A Acker; Mariell L Jessup; Igor D Gregoric; Pranav Loyalka; O H Frazier; Valluvan Jeevanandam; Allen S Anderson; Robert L Kormos; Jeffrey J Teuteberg; Wayne C Levy; David C Naftel; Richard M Bittman; Francis D Pagani; David R Hathaway; Steven W Boyce
Journal:  Circulation       Date:  2012-05-22       Impact factor: 29.690

4.  HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial.

Authors:  Mark S Slaughter; Francis D Pagani; Edwin C McGee; Emma J Birks; William G Cotts; Igor Gregoric; O Howard Frazier; Timothy Icenogle; Samer S Najjar; Steven W Boyce; Michael A Acker; Ranjit John; David R Hathaway; Kevin B Najarian; Keith D Aaronson
Journal:  J Heart Lung Transplant       Date:  2013-07       Impact factor: 10.247

5.  Survival results after implantation of intrapericardial third-generation centrifugal assist device: an INTERMACS-matched comparison analysis.

Authors:  Angelo M Dell'Aquila; Stefan R B Schneider; Jörg Stypmann; Björn Ellger; Bassam Redwan; Dominik Schlarb; Sven Martens; Jürgen R Sindermann
Journal:  Artif Organs       Date:  2013-10-11       Impact factor: 3.094

6.  Use of centrifugal left ventricular assist device as a bridge to candidacy in severe heart failure with secondary pulmonary hypertension.

Authors:  Ramesh S Kutty; Jayan Parameshwar; Clive Lewis; Pedro A Catarino; Catherine D Sudarshan; David P Jenkins; John J Dunning; Steven S Tsui
Journal:  Eur J Cardiothorac Surg       Date:  2013-01-22       Impact factor: 4.191

7.  Successful treatment of early thrombosis of HeartWare left ventricular assist device with intraventricular thrombolytics.

Authors:  Abdallah Kamouh; Ranjit John; Peter Eckman
Journal:  Ann Thorac Surg       Date:  2012-07       Impact factor: 4.330

8.  Device exchange after primary left ventricular assist device implantation: indications and outcomes.

Authors:  John M Stulak; Jennifer Cowger; Jonathon W Haft; Matthew A Romano; Keith D Aaronson; Francis D Pagani
Journal:  Ann Thorac Surg       Date:  2012-10-11       Impact factor: 4.330

9.  Mechanical circulatory support and heart transplantation: donor and recipient factors influencing graft survival.

Authors:  Simon Maltais; Nikhil P Jaik; Irene D Feurer; Mark A Wigger; Thomas G DiSalvo; Kelly H Schlendorf; Rashid M Ahmad; Daniel J Lenihan; John M Stulak; Mary E Keebler
Journal:  Ann Thorac Surg       Date:  2013-07-31       Impact factor: 4.330

10.  Comparative cost-effectiveness of the HeartWare versus HeartMate II left ventricular assist devices used in the United Kingdom National Health Service bridge-to-transplant program for patients with heart failure.

Authors:  Ruth Pulikottil-Jacob; Gaurav Suri; Martin Connock; Ngianga-Bakwin Kandala; Paul Sutcliffe; Hendramoorthy Maheswaran; Nicholas R Banner; Aileen Clarke
Journal:  J Heart Lung Transplant       Date:  2014-01-19       Impact factor: 10.247

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.